scholarly journals Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium

2021 ◽  
Author(s):  
Ramesh Boinpally ◽  
Kaifeng Lu
Keyword(s):  
Pharmacokinetic Interaction ◽  
Esomeprazole Magnesium

scholarly journals Pharmacokinetic and safety study of co-administration of albendazole, diethylcarbamazine, Ivermectin and azithromycin for the integrated treatment of Neglected Tropical Diseases

2020 ◽  
Author(s):  
Lucy N John ◽  
Catherine Bjerum ◽  
Pere Millat Martinez ◽  
Rhoda Likia ◽  
Linda Silus ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Large Scale ◽  
Neglected Tropical Diseases ◽  
Pharmacokinetic Interaction ◽  
Integrated Treatment ◽  
Secondary Outcome ◽  
Pharmacokinetic Data ◽  
Tropical Diseases ◽  
Open Label ◽  
Significant Difference

Abstract Background Pharmacokinetic data are a pre-requisite to integrated implementation of large-scale mass drug administration (MDA) for neglected tropical diseases (NTDs). We investigated the safety and drug interactions of a combination of azithromycin (AZI) targeting yaws and trachoma, with the newly approved ivermectin, albendazole, diethylcarbamazine (IDA) regime for Lymphatic Filariasis. Methodology An open-label, randomized, 3-arm pharmacokinetic interaction study in adult volunteers was carried out in Lihir Island, Papua New Guinea. Healthy adult participants were recruited and randomized to (I) IDA alone, (II) IDA combined with AZI, (III) AZI alone. The primary outcome was lack of a clinically relevant drug interaction. The secondary outcome was the overall difference in the proportion of AEs between treatment arms. Results Thirty-seven participants, eighteen men and nineteen women, were randomized and completed the study. There were no significant drug-drug interactions between the study arms. The GMR of Cmax, AUC0–t, and AUC0–∞ for IVM, DEC, ALB-SOX, and AZI were within the range of 80–125% (GMR for AUC0–∞ for IVM, 87.9; DEC, 92.9; ALB-SOX, 100.0; and AZI, 100.1). There was no significant difference in the frequency of AEs across study arms (AZI and IDA alone arms 9/12 (75%), co-administration arm 12/13 (92%); p = 0.44). All AEs were grade 1 and self-limiting. Conclusions Co-administration of AZI with IDA did not show evidence of significant drug-interactions. There were no serious AEs in any of the study arms. Our data support further evaluation of the safety of integrated MDA for NTDs. Clinical Trials Registration. NCT03664063

Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide

2011 ◽  
Vol 26 (2) ◽  
pp. 214-219 ◽  
Author(s):  
Mohamed G. Hassan ◽  
Kamla M. Emara ◽  
Horria A. Mohamed ◽  
Hanaa M. Abdel-Wadood ◽  
Rie Ikeda ◽  
...  
Keyword(s):  
Pharmacokinetic Interaction ◽  
Rat Plasma ◽  
Fluorescence Method

Possible Mechanisms for the Pharmacokinetic Interaction Between Phenytoin and Folinate in Rats

2007 ◽  
Vol 29 (4) ◽  
pp. 404-411 ◽  
Author(s):  
Daisuke Yamasaki ◽  
Masayuki Tsujimoto ◽  
Shigehiro Ohdo ◽  
Hisakazu Ohtani ◽  
Yasufumi Sawada
Keyword(s):  
Pharmacokinetic Interaction

0-73. Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer

The Breast ◽  
1997 ◽  
Vol 6 (4) ◽  
pp. 245 ◽  
Author(s):  
M. Dowsett ◽  
C.U. Pfister ◽  
S.R.D. Johnston ◽  
S.J. Houston ◽  
D.W. Miles ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Pharmacokinetic Interaction ◽  
Advanced Breast

scholarly journals Pharmacokinetic interaction between valproic acid and ertapenem

2006 ◽  
Vol 30 (5) ◽  
pp. 313-315 ◽  
Author(s):  
M.A. Cabanes Mariscal ◽  
P. Sánchez López ◽  
P. Álvarez Herranz ◽  
G. Chamorro Merino
Keyword(s):  
Valproic Acid ◽  
Pharmacokinetic Interaction

scholarly journals Pharmacokinetic Interactions between Primaquine and Chloroquine

2014 ◽  
Vol 58 (6) ◽  
pp. 3354-3359 ◽  
Author(s):  
Sasithon Pukrittayakamee ◽  
Joel Tarning ◽  
Podjanee Jittamala ◽  
Prakaykaew Charunwatthana ◽  
Saranath Lawpoolsri ◽  
...  
Keyword(s):  
Oral Dose ◽  
Hospital Admissions ◽  
Geometric Mean ◽  
Pharmacokinetic Interaction ◽  
Plasmodium Ovale ◽  
Open Label ◽  
Content Type ◽  
Reference Number ◽  
Electrocardiographic Changes ◽  
To Receive

ABSTRACTChloroquine combined with primaquine has been the standard radical curative regimen forPlasmodium vivaxandPlasmodium ovalemalaria for over half a century. In an open-label crossover pharmacokinetic study, 16 healthy volunteers (4 males and 12 females) aged 20 to 47 years were randomized into two groups of three sequential hospital admissions to receive a single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together. The coadministration of the two drugs did not affect chloroquine or desethylchloroquine pharmacokinetics but increased plasma primaquine concentrations significantly (P≤ 0.005); the geometric mean (90% confidence interval [CI]) increases were 63% (47 to 81%) in maximum concentration and 24% (13 to 35%) in total exposure. There were also corresponding increases in plasma carboxyprimaquine concentrations (P≤ 0.020). There were no significant electrocardiographic changes following primaquine administration, but there was slight corrected QT (QTc) (Fridericia) interval lengthening following chloroquine administration (median [range] = 6.32 [−1.45 to 12.3] ms;P< 0.001), which was not affected by the addition of primaquine (5.58 [1.74 to 11.4] ms;P= 0.642). This pharmacokinetic interaction may explain previous observations of synergy in preventingP. vivaxrelapse. This trial was registered at ClinicalTrials.gov under reference number NCT01218932.

Pharmacokinetic Interaction Between High-Dose Methotrexate and Oxacillin

2002 ◽  
Vol 24 (4) ◽  
pp. 570-572 ◽  
Author(s):  
Karine Titier ◽  
Fabrice Lagrange ◽  
Fabienne Péhourcq ◽  
Nicholas Moore ◽  
Mathieu Molimard
Keyword(s):  
Pharmacokinetic Interaction ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

The pharmacokinetic interaction between levofloxacin and sunitinib

2015 ◽  
Vol 67 (3) ◽  
pp. 542-544 ◽  
Author(s):  
Andrzej Czyrski ◽  
Katarzyna Kondys ◽  
Edyta Szałek ◽  
Agnieszka Karbownik ◽  
Edmund Grześkowiak
Keyword(s):  
Pharmacokinetic Interaction
Sign in / Sign up

Export Citation Format

Share Document